Ropes & Gray Represents EQRx in Partnership with Absci to Develop Protein-Based Drugs
Ropes & Gray advised EQRx in a strategic drug discovery and development partnership to use Absci’s artificial intelligence and synthetic biology platform to create more affordable protein-based therapies for patients. The transaction was announced on Oct. 6.
EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology. At Absci’s option, it may make additional investments at progressive stages of development in exchange for an increased share of product sales.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate James McLeod (both of Boston).